Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. abt

ABT

AXVIRIUM BIOACTIVE TECNOLOGY_ The first medical device able to eliminate the fluids biological hazard

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ABT project word cloud

Explore the words cloud of the ABT project. It provides you a very rough idea of what is the project "ABT" about.

worldwide    disposal    decreasing    eur    occupational    cut    16    nosocomial    innovative    health    bioactive    hiv    reg    ing    caused    fluids    cagr    environment    hepatitis    validate    20    facilities    industry    proper    biomedical    hazardous    direct    validation    diseases    world    structures    plus    market    adantium    time    hire    nearly    feasibility    segments    anticipated    risks    reducing    solution    almost    completely    abt    2022    barriers    medical    skilled    tons    million    healthcare    8    virus    care    valuation    improper    global    molecules    sterilize    tecnology    natural    degradation    14    posing    23    21    200    day    2018    investigation    employees    economic    commercial    7000    ip    100    waste    survey    infection    organisation    strategy    infectious    rnases    individuals    saving    axvirium    imply    community    accidents    66    18    competitors    estimate    reduce    impacts    positive    identification    device    customer    annually    fluid    39    incorrect    biological    efficiency    amongst    accounted    cross    billion    axivirium   

Project "ABT" data sheet

The following table provides information about the project.

Coordinator		 ENPROJECT MEDICALI SRL 

Organization address
address: VIALE CARLO FAINA 30
city: MARSCIANO
postcode: 6055
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Italy [IT]
 Project website https://www.enprojectmedicali.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ENPROJECT MEDICALI SRL IT (MARSCIANO) coordinator 50˙000.00

Map

 Project objective

The aim of the project is to validate the technical and economic feasibility of AXVIRIUM BIOACTIVE TECNOLOGY (ABT) an innovative biomedical device, based on the Adantium® Plus and Axivirium BIOACTIVE® molecules, enable to cut biological risks, improve efficiency and reduce cost of health care biomedical fluids disposal. Medical waste is posing a growing problem worldwide resulting in nearly 7000 tons every day of infectious /hazardous medical waste and 10 billion euro annually in disposal cost across the European health care industry. According to the World Health Organisation (WHO), incorrect and improper management of healthcare biological fluids can have direct impacts on the community, individuals working in health care facilities, and the natural environment. It estimated that at world level accidents caused by not proper biological risks management accounted for 66,000 cases of infection with the hepatitis B virus, 16,000 cases of infection with hepatitis C virus and 200 to 5,000 cases of HIV infection amongst the personnel of health-care facilities. Compared to competitors ABT is the unique solution able to reach 100% degradation of RNases almost in real time and completely sterilize biological fluids. This imply saving operational cost up to 20%, decreasing occupational diseases by 39% and reducing cross- nosocomial infection by 14%. In 2018, the valuation of the global fluid management market was EUR 10 billion and is anticipated to reach EUR 18 billion by 2022, at a positive CAGR of 4.8% in the next three years. The estimated market potential for ABT is about 21 million euro and we estimate to hire 23 high skilled employees. The feasibility study comprises an investigation of market structures, segments and barriers, a customer survey and product validation, the identification of key commercial partners and the development of an IP strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ABT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ABT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More